Clinical trials

Condition   Drug Name  
Study 12B75 in psoriasis: The NCT00320216 study
Design Randomized; Double-blind; Multicenter
Patients 300
Treatment Regimen 12B75, 45 mg s.c.; 12B75, 45 mg s.c. 1x/wk x 4 wks; 12B75, 90 mg s.c.; 12B75, 90 mg s.c. 1x/wk x 4 wks; Placebo
Conclusions A phase ll study will assess the safety and efficacy of single and multiple doses of 12B75 in patients with palque-type psoriasis
Reference(s) A study of the safety and efficacy of CNTO 1275 in subjects with severe plaque-type psoriasis (NCT00320216)
ClinicalTrials.gov Web Site 2007